Pharmaceuticals

SC Pharmaceuticals

SC Pharmaceuticals released FY2026 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 48.44 M, actual EPS CNY 0.0083

SC Pharmaceuticals FY2026 Q1 Earnings Release on April 29 After-Market (BJT)

SC Pharmaceuticals released FY2025 earnings on April 2 After-Market (BJT), actual revenue CNY 276.76 M, actual EPS CNY 0.05

SC Pharmaceuticals released FY2025 Q4 earnings on April 2 After-Market (BJT), actual revenue CNY 107.86 M, actual EPS CNY 0.0763

SC Pharmaceuticals released FY2025 Q3 earnings on October 29 Pre-Market BJT, actual revenue CNY 84.78 M, actual EPS CNY 0.0387

SC Pharmaceuticals released FY2025 9 Months earnings on October 29 Pre-Market (BJT), actual revenue CNY 168.9 M, actual EPS CNY -0.0057

SC Pharmaceuticals to Release FY2025 Q3 Earnings Report on October 30 Pre-Market BJT

SC Pharmaceuticals released FY2025 Semi-Annual earnings on July 30 Pre-Market (BJT), actual revenue CNY 84.12 M, actual EPS CNY -0.0445

SC Pharmaceuticals released FY2025 Q2 earnings on July 30 Pre-Market (BJT), actual revenue CNY 47.45 M, actual EPS CNY -0.0203

SC Pharmaceuticals FY2025 Semi-Annual Earnings Release on July 31, 2025 (BJT)

*ST Shuang Cheng Announces 2025 H1 Earnings Forecast

*ST Shuang Cheng Expected to Report Net Loss of RMB 13 to 19 Million for H1 2025

*ST Shuang Cheng's Injectable Paclitaxel Receives FDA Approval for Market Access

Shuang Cheng Obtains Market Authorization for Eptifibatide Injection in Australia

*ST DoubleWin's Albumin-bound Paclitaxel Injection Receives FDA Marketing Approval

*ST Shuang Cheng Holds Earnings Briefing to Outline Future Development Strategies

*ST Shuang Cheng Obtained Australian Market Approval for Injectable Bivalirudin

Changhe Pharmaceutical Announced Q1 2025 Earnings Report

SC Pharmaceuticals released FY2024 Q4 earnings on April 28 After-Market BJT, actual revenue CNY 47.25 M, actual EPS CNY -0.0998

SC Pharmaceuticals released FY2025 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 36.68 M, actual EPS CNY -0.0242

002693

ST SC Pharmaceuticals announced that the company recently received the "Drug GMP Compliance Inspection Notification" issued by the Hainan Provincial Drug Administration. The inspection scope includes lyophilized powder injections, active pharmaceutical ingredients, and related production lines. The inspection date is from June 11 to 13, 2025, and the inspection conclusion meets the requirements of the Good Manufacturing Practice (GMP) for drug production quality management. This successful inspection indicates that the company's production quality management system complies with the requirements of the Good Manufacturing Practice for drug production, which is beneficial for maintaining stable production capacity and meeting market demand

Zhitong

ST SC Pharmaceuticals: Passed the drug GMP compliance inspection

ST SC Pharmaceuticals released its semi-annual report for 2025, with operating revenue of 84.1221 million yuan, a year-on-year decrease of 11.35%. The net loss attributable to shareholders of the listed company was 18.4666 million yuan, a year-on-year increase of 8.97%. The net loss after deducting non-recurring gains and losses was 21.0158 million yuan, a year-on-year increase of 18.34%. The basic loss per share was 0.0445 yuan

ST SC Pharmaceuticals released its half-year performance, with a net loss attributable to shareholders of 18.4666 million yuan, an increase of 8.97%

ST SC Pharmaceuticals recently obtained the marketing authorization for Eptifibatide Injection issued by the Therapeutic Goods Administration (TGA) of Australia. This drug is suitable for patients undergoing non-emergency percutaneous coronary intervention, as well as for the treatment of unstable angina or non-Q wave myocardial infarction. This authorization will help the company expand its overseas market and improve its performance

ST SC Pharmaceuticals: Eptinezumab injection has obtained marketing authorization from the Therapeutic Goods Administration (TGA) of Australia

ST SC Pharmaceuticals recently announced that the company has received approval from the U.S. FDA for the abbreviated new drug application (ANDA) for injectable paclitaxel (albumin-bound). This product has undergone comprehensive technical review, confirming its bioequivalence and therapeutic equivalence to the original drug. Injectable paclitaxel (albumin-bound) forms nanoparticles by encapsulating paclitaxel in albumin, significantly reducing cytotoxic side effects, enhancing anti-tumor effects, and providing targeting capabilities to direct release to tumor cells

ST SC Pharmaceuticals: Injectable Paclitaxel (Albumin-Bound) ANDA approved for market by the U.S. FDA

ST SC Pharmaceuticals recently obtained marketing authorization from the Therapeutic Goods Administration (TGA) of Australia for injectable bivalirudin. This drug is used for the treatment of patients with moderate to high-risk acute coronary syndrome, applicable to those with unstable angina and non-ST elevation myocardial infarction, and can be used in combination with aspirin and P2Y12 antagonists

ST SC Pharmaceuticals: Injectable Bivalirudin has obtained market approval from the Therapeutic Goods Administration (TGA) of Australia

002581

CRO concept stocks opened lower, SC Pharmaceuticals and Sinobioway Medicine hit the daily limit down, while Boji Pharmaceutical, Hongbo Pharmaceutical, and Haofan Biotechnology all opened lower

Sinobioway Medicine

Highfine

BOJI CRO

CRO concept stocks opened lower, SC Pharmaceuticals and Sinobioway Medicine hit the daily limit down

SC Pharmaceuticals hit the daily limit today, with a transaction amount of 936 million yuan and a turnover rate of 23.40%. According to the post-market 龙虎榜 data, the Shenzhen Stock Connect special seat bought 124 million yuan and sold 32.5246 million yuan, with one institutional special seat net selling 11.4106 million yuan

SC Pharmaceuticals hit the daily limit today, with one institutional special seat net selling 11.4106 million yuan

SC Pharmaceuticals hit the daily limit up during trading, achieving a ceiling price, with a transaction amount of 906 million yuan

SC Pharmaceuticals performs a ceiling and floor limit

300757

36Kr learned that the three major A-share indices opened lower collectively, with the Shanghai Composite Index down 0.3%, the Shenzhen Component Index down 0.14%, and the ChiNext Index down 0.2%; pharmaceutical stocks surged significantly, with weight loss drugs and Alzheimer's direction leading the gains, JinKai Biotechnology rising over 10%, SC Pharmaceuticals rising over 9%, and Huadong Medicine rising over 4%; the precious metals and semiconductor sectors saw significant declines, with SiRuPu down over 3%, Shandong Gold and Zhongjin Gold down over 1%. The major asset restructuring was approved, and RoboTechnik opened up 9.38%

36Kr

RoboTechnik

HUADONG MEDICINE

Kingchem

3PEAK

SD GOLD

ZHONGJIN GOLD

The three major A-share indices opened lower collectively, RoboTechnik opened up 9.38%

SC Pharmaceuticals announced that due to the stock trading price increasing by more than 20% for two consecutive days on April 15 and 16, 2025, it may be subject to delisting risk warning after the disclosure of the 2024 annual report. The net profit attributable to shareholders of the listed company for 2024 is expected to be negative, with operating revenue between 140 million and 180 million yuan

SC Pharmaceuticals: May be subject to delisting risk warning after the disclosure of the 2024 annual report

SC Pharmaceuticals(002693.SZ)